N/A N=36 Treatment

Stroke and CPAP Outcome Study 3

Ischemic Stroke · Intra Cerebral Hemorrhage · Obstructive Sleep Apnea · Adherence, Treatment · Motivation

Bottom Line

View on ClinicalTrials.gov: NCT06029959 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Oct 2025

Primary outcome: Primary: CPAP Adherence — 3.1 nightly hours of CPAP use

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Continuous positive airway pressure (CPAP) (Device); CPAP technical support intervention (Behavioral); Motivational Enhancement Therapy (MET) (Behavioral); Mobile Health intervention (Behavioral)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: University of Washington
Primary completion: Sep 2024

Outcome Measures

Outcome	Result	p-value
PRIMARY CPAP Adherence	3.1	—

Summary

A problem with breathing during sleep, called obstructive sleep apnea (OSA), likely increases the risk of stroke and is common in people who have had a stroke, present in about 2/3 of stroke survivors. There is also evidence that OSA predicts worse outcome after stroke. The question being addressed in the Stroke and CPAP Outcome Study 3 (SCOUTS3) is how to improve use of continuous positive airway pressure (CPAP) therapy to treat OSA when started during intensive stroke rehabilitation.

Eligibility Criteria

Inclusion Criteria

Age 18 years or older
Head CT or brain MRI demonstrating an acute ischemic infarction or intraparenchymal hemorrhage within past 30 days
Person providing consent (patient or legally authorized representative) able to be consented in English or Spanish

Exclusion Criteria

Unable to obtain informed consent from participant or surrogate
Incarcerated
Known pregnancy
Current mechanical ventilation, tracheostomy or supplemental oxygen use > 4L/min
Current use of positive airway pressure or use within 14 days prior to stroke
History of pneumothorax, bullous emphysema or other serious co-morbid conditions which limit CPAP use
Stroke related to tumors, vascular malformations or subarachnoid hemorrhage
Active use of sedative drugs that can interfere with testing for obstructive sleep apnea (OSA)
Anticipated inpatient rehabilitation length of stay < 3 nights

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT06029959). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.